|
|
|
Insider
Information: |
Bishop Hans Edgar |
Relationship: |
Director |
City: |
Seattle |
State: |
WA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
7 |
|
Direct
Shares |
10,745,618 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$7,305,757 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
10,745,618 |
|
|
Total
Value |
$7,305,757 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Dendreon Corp |
DNDN |
Chief Operating Officer |
2011-07-29 |
151,189 |
2010-01-29 |
0 |
Premium* |
|
Avanir Pharmaceuticals |
AVNR |
Director |
2014-02-12 |
93,350 |
2013-02-14 |
0 |
Premium* |
|
Juno Therapeutics, Inc. |
JUNO |
CEO & President, Direc... |
2018-03-05 |
0 |
|
0 |
Premium* |
|
Agilent Technologies Inc |
A |
Director |
2024-03-15 |
24,976 |
2017-07-18 |
0 |
Premium* |
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
Sana Biotechnology, Inc. |
SANA |
|
2024-10-07 |
5,790,489 |
|
0 |
Premium* |
|
Lyell Immunopharma, Inc. |
LYEL |
Director |
2022-09-08 |
4,685,614 |
2021-06-21 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
64 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
DNDN |
Dendreon Corp |
Chief Operating Officer |
|
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
110,000 |
110,000 |
0 |
- |
|
DNDN |
Dendreon Corp |
Chief Operating Officer |
|
2010-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
27,000 |
137,000 |
0 |
- |
|
DNDN |
Dendreon Corp |
Chief Operating Officer |
|
2011-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
28,051 |
165,051 |
0 |
- |
|
DNDN |
Dendreon Corp |
Chief Operating Officer |
|
2011-02-10 |
4 |
D |
$35.01 |
$323,107 |
D/D |
(9,229) |
155,822 |
0 |
- |
|
DNDN |
Dendreon Corp |
Chief Operating Officer |
|
2011-04-29 |
4 |
D |
$42.27 |
$98,998 |
D/D |
(2,342) |
153,480 |
0 |
- |
|
DNDN |
Dendreon Corp |
Chief Operating Officer |
|
2011-07-29 |
4 |
D |
$37.65 |
$86,256 |
D/D |
(2,291) |
151,189 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
Director |
|
2013-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
19,450 |
64,450 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
Director |
|
2014-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
28,900 |
93,350 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
See RemarksOfficer |
|
2014-12-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,724,859 |
|
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO and President |
|
2015-12-15 |
4 |
OE |
$6.36 |
$343,440 |
D/D |
54,000 |
2,778,859 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO and President |
|
2015-12-15 |
4 |
AS |
$44.77 |
$4,183,411 |
D/D |
(91,500) |
2,687,359 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
See Remarks |
|
2016-02-29 |
4 |
OE |
$6.36 |
$343,440 |
D/D |
54,000 |
2,741,359 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
See Remarks |
|
2016-02-29 |
4 |
AS |
$35.27 |
$3,205,005 |
D/D |
(90,750) |
2,650,609 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-06-09 |
4 |
OE |
$6.36 |
$343,440 |
D/D |
54,000 |
2,704,609 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-06-09 |
4 |
AS |
$45.80 |
$4,212,344 |
D/D |
(90,750) |
2,613,859 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-06-30 |
4/A |
AS |
$38.41 |
$4,431,116 |
D/D |
(115,250) |
2,542,609 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-06-30 |
4 |
D |
$38.41 |
$4,431,116 |
D/D |
(115,250) |
2,542,609 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-06-30 |
4 |
OE |
$6.36 |
$279,840 |
D/D |
44,000 |
2,657,859 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-08-31 |
4 |
OE |
$6.36 |
$115,580 |
D/D |
18,173 |
2,560,782 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-08-31 |
4 |
AS |
$30.06 |
$1,282,554 |
D/D |
(42,673) |
2,518,109 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-09-08 |
4 |
OE |
$6.36 |
$146,547 |
D/D |
23,042 |
2,541,151 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-09-08 |
4 |
AS |
$30.06 |
$692,578 |
D/D |
(23,042) |
2,518,109 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-09-19 |
4 |
OE |
$6.36 |
$2,722 |
D/D |
428 |
2,518,537 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-09-19 |
4 |
AS |
$30.00 |
$12,840 |
D/D |
(428) |
2,518,109 |
0 |
- |
|
JUNO |
Juno Therapeutics, Inc. |
CEO & President |
|
2016-09-20 |
4 |
AS |
$30.00 |
$189,003 |
D/D |
(6,300) |
2,518,109 |
0 |
- |
|
64 Records found
|
|
Page 1 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|